Status:
COMPLETED
Myocardial Protection With Adenosine Preconditioning
Lead Sponsor:
Xijing Hospital
Conditions:
Heart Defects, Congenital
Cardiac Surgical Procedures
Eligibility:
All Genders
1-24 years
Phase:
PHASE1
PHASE2
Brief Summary
Adenosine has been proved to be an important mediator of myocardial protection induced by ischemic preconditioning. The hypothesis of this study is that adenosine preconditioning can provide additiona...
Detailed Description
Adenosine has been used for diagnosis and treatment of cardiovascular diseases for many years. New progresses in myocardial protection in the settings of acute myocardial infarction treatment put forw...
Eligibility Criteria
Inclusion
- Clinical diagnosis of congenital heart defects eligible for surgery treatment under cardiopulmonary bypass and cardioplegia
- Body weight less than or equals to 10kg
Exclusion
- Cardiac surgery is performed without cardiopulmonary or cardioplegia
- Body weight more than 10Kg
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT00881686
Start Date
June 1 2008
End Date
December 1 2008
Last Update
April 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiovascular Surgery, Xijing Hospital
Xi'an, Shannxi, China, 710032